This will streamline case processing and enable DMP to better utilize European systems and processes, initially related to human medicines. The new platform provides greater opportunities to optimize case handling. Metadata from submissions will be used for automatic case creation and workflow selection.
At the same time, this requires applicants to adhere to the guidelines for completing files accompanying a submission.
"Having correct data from the start ensures that the rest of the case processing follows the correct path", says project owner and strategic director Randi Tandle.
We ask companies to communicate this internally within their organizations and between them.
Challenging transition phase
DMP transitioned to the new platform on September 17th. Prior to this, all completed and ongoing cases were transferred from the previous system to the new platform. DMP asks the pharmaceutical industry to remain vigilant and report any issues that seem incorrect, such as misdirected emails.
"The transition to a new system is challenging. We must expect somewhat reduced capacity, which may also lead to some delays during a transitional period. At the same time, this is a significant and important investment for DMP that can bring benefits for both us and the industry", concludes Tandle.